This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
BackgroundThe utility of screening for the degree of common carotid artery (CCA) stenosis as a predictor of cardiovascular disease (CVD) in a general population remains unclear.Methods and ResultsWe studied 4775 Japanese men and women whose CCA was measured using bilateral carotid ultrasonography at baseline (April 1994–August 2001).
These key takeaways from the research letter on IVL-facilitated valvuloplasty for severely calcified mitral valve stenosis are published in the Journal of the American College of Cardiology (JACC) Cardiovascular Interventions. an interventional cardiologist and structural heartdisease expert at Henry Ford Health. “We
At present, machine learning, deep learning, and other AI technologies have been tried to be applied to intelligent diagnostic and decision making, image interpretation, accurate classification, and prognostication of cardiovascular diseases, which has led to broad application prospects and innovation potential.
Cleerly, a digital healthcare company focused on heartdisease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging. With Plaque Features Associated with False Positives.
The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heartdisease due to discrete de novo native coronary artery lesions. of the U.S.
We present a complex case of NSTEMI with multi-vessel coronary artery disease treated with PCI via the Carlino technique.Case Description:A 60-year-old female with a history of hypertension, diabetes mellitus, and ischemic heartdisease presented with severe chest pain that radiated to the neck and was associated with nausea and vomiting.
24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.
mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heartdisease, said Matthew J. mg improved coronary plaque stability in patients with acute coronary syndrome. mg on atherosclerotic plaque. Budoff, M.D.,
Food and Drug Administration (FDA) 510(k) clearance of its CaRi-Plaquetechnology, an AI-assisted image analysis application to aid the diagnosis of coronary artery disease (CAD). For decades, heartdisease has been treated reactively, waiting for symptoms to appear before taking action. But with AI, we can change that.
Coronary computed tomography angiography (CCTA) was a major advancement in CAD diagnostics, helping physicians estimate if a stenosis was significant and requiring intervention. Now Heartflow Plaque Analysis leverages AI to quantify and characterize the amount and type of plaque present in the arteries from a single CCTA scan.
mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heartdisease, said Matthew J. mg improved coronary plaque stability in patients with acute coronary syndrome. mg on atherosclerotic plaque. Budoff, M.D.,
Results:Among the 36,403 participants (14,676 males, 40.3%), the prevalence of stroke, heartdisease, hypertension, diabetes mellitus, and dyslipidemia was 7.4%, 6.4%, 55.7%, 17.3%, and 40.2% 2021-KY-1289-001).Results:Among respectively.
The companies will jointly support a series of educational forums among clinicians beginning later this year highlighting the significant new scientific breakthroughs that are radically transforming the traditional approach to heartdisease prevention and prediction.
Share Let’s first state our goal when we are in the business of ‘HeartDisease Prevention’: To delay the onset of coronary artery disease (atherosclerosis/plaque) that might rupture and cause a heart attack. And the less plaque you have, the lower the risk of a heart attack.
While it seems intuitively obvious that doing more tests to find heartdisease will decrease the likelihood of dying from heartdisease, the reality is anything but obvious. To make matters even more complicated, plaque in younger patients may be non-calcified and invisible to CT-calcium scans.
The clinical presentation of ischaemic heartdisease has a broad spectrum, encompassing not only traditional epicardial coronary artery disease (CAD) characterised by stenosis or occlusion but also structural and functional disorders at both macrovessel and microvessel levels, as highlighted in the latest European guidelines.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
78 
Let's personalize your content